Innate Pharma S.A.

NASDAQ:IPHA

Biotechnology

Healthcare
$1.03 +1.91%

+$0.03 today

Market cap
$115.05M
Beta
0.89
P/E (TTM)
-3.0
EPS (TTM)
-$0.54
52W Low $1.17High $2.63

Volume 0.50M

Average 0.07M

IPHA Debt Repayment

Cash used to repay borrowings during the period.

Innate Pharma S.A.NASDAQ: IPHA

Debt Repayment · Q4 FY2025 · quarter ended Dec 2025

Debt repayment declines year over year

Q4 FY2025 debt repayment of €4.7M (cash outflow) fell 47.4% year over year. Over 3 fiscal years it compounded at +61.7% a year.

Context

  • Debt repayment amounted to 307.1% of revenue in FY2025, up 236.3 pp from a year earlier.
  • Debt repayment grew in size in 2 of the last 3 fiscal years.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-€4.7M— QoQ
Last fiscal yearDec 2025
-€8.56M-4.2% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-47.4%——
1 year-4.2%——
3-year CAGR+61.7%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

EUR · from the cash flow

Latest · FY2025
(8.56M) EUR
Year-over-year change
+4.2%

Debt Repayment vs competitors

How IPHA compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -4.2% is the 4th highest of 5, against a peer median of +46.9%.
  • Debt repayment amounts to 307.1% of revenue for IPHA, versus a peer median of 267.8%.
IPHA Competitors
Debt Repayment for IPHA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$75M USD——4204.0%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$16.97M USD+94.0%—535.6%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$9.87M USD-50.0%——
IPHAInnate Pharma S.A.FY2025€8.56M EUR-4.2%+61.7%307.1%
MOLNMolecular Partners AGLTM Mar 2026CHF 1.21M CHF-0.1%+0.6%—
NVCTNuvectis Pharma, Inc.LTM Mar 2026$0 USD———
CGENCompugen Ltd.LTM Dec 2025$0 USD——0.0%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$0 USD+100.0%——
CRDFCardiff Oncology, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding IPHA) —+46.9%+0.6%267.8%

Competitors are the stored peer set for IPHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(52.81M)(58.1M)(7.57M)(49.47M)(49.18M)
Depreciation & Amortization4.6M45.41M5.09M1.99M5.09M
Deferred Income Tax(1.68M)0000
Stock-Based Compensation2.62M4.25M4.26M3.94M4.26M
Change in Working Capital(9.88M)(12.5M)(32.09M)39.16M(10.21M)
Accounts Receivables3.39M(4.2M)(13.67M)00
Inventory(6.27M)0000
Accounts Payables(946K)(7.66M)(3.89M)00
Other Working Capital(6.06M)(636K)(10.54M)39.16M(10.21M)
Other Non-Cash Items(1.3M)1.8M(2.24M)(2.53M)(630.52K)
Operating Cash Flow(58.46M)(19.15M)(32.56M)(6.9M)(50.67M)
Capital Expenditures(1.33M)(1.12M)(2.35M)(391K)(134.47K)
Acquisitions (Net)7K0004.8K
Purchases of Investments00000
Sales of Investments03M22.77M9.59M13.51M
Other Investing Activities406K(1K)(1.79M)1K(6.38M)
Investing Cash Flow(917K)1.88M20.63M9.2M7M
Debt Repayment26.63M(2.03M)(2.36M)(8.94M)(8.56M)
Common Stock Issued499K198K395K2.93M14.39M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities187K198K395K2.93M0
Financing Cash Flow26.82M(1.83M)(1.97M)(6.01M)5.83M
Effect of Forex Changes(483K)(428K)274K(505K)7.41M
Net Change in Cash(33.04M)(19.53M)(13.62M)(4.21M)(30.44M)
Free Cash Flow(59.79M)(20.28M)(34.91M)(7.29M)(50.81M)

Innate Pharma S.A.

NASDAQ:IPHA

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.